EHL BIO Collaborates with Leading University Hospitals: Chungnam, Dankook, and Chonnam

Vision of Global Regenerative Medicine Collaboration

EHL BIO is dedicated to becoming a leader in biotechnology that benefits humanity through advanced regenerative medicine. A key component of this mission is establishing strong partnerships with leading medical institutions. Throughout 2021, EHL BIO continuously expanded its academic cooperation network by signing MOUs with top university hospitals in South Korea to jointly pursue new innovations for treating complex diseases and age-related degeneration.

The synergy between EHL BIO's research team, comprising over 85 experts, and the extensive clinical experience of university hospitals facilitates a deep exchange of knowledge regarding stem cell and immune cell applications. This collaboration is not just about scientific development; it is a commitment to enhancing quality of life and promoting long-term health under the highest safety standards.

Key Milestones with Chungnam and Dankook University Hospitals

Official cooperation began on June 9, 2021, when EHL BIO signed an MOU with Chungnam National University Hospital to jointly research and develop advanced regenerative medicine technologies. This marked the starting point for systematically integrating cutting-edge cell culture technology into clinical research processes.

Subsequently, on August 20, 2021, EHL BIO reached a cooperation agreement with Dankook University Hospital to develop joint research projects in the same field. Collaborating with these two prestigious university hospitals underscores EHL BIO’s recognition by national medical institutions, particularly in providing solutions for tissue repair and immune balance through cell therapy.

Collaboration with leading university hospitals is key to transforming research into tangible treatments for a better quality of life.

Expanding Network to Chonnam National University Hospital

On November 25, 2021, EHL BIO entered into an MOU with Chonnam National University Hospital to pursue joint research and innovation in advanced regenerative medicine. This partnership focuses on integrating EHL BIO’s patented technologies for isolating and culturing stem cells with university-level clinical studies.

Beyond university-affiliated hospitals, EHL BIO also signed cooperation agreements with other specialized institutions like Seoul Songdo Hospital and Madi Sarang Hospital around the same period, creating a comprehensive regenerative medicine research ecosystem across South Korea. These networks ensure that human research strictly adheres to the 'Advanced Regenerative Medicine and Advanced Biopharmaceuticals Act' regulated by the Ministry of Health and Welfare and the Korean MFDS.

Confidence in Innovation and GMP Standard Production

The success in attracting leading university hospitals as partners stems from EHL BIO’s outstanding technology, featuring Class 100 GMP-certified production facilities and an officially recognized Cell Processing Center (CPC). This technology enables cell culture yields up to 1,000 times higher than industry standards while maintaining excellent cell viability.

With a stable production base capable of handling up to 6,000 lots per year, EHL BIO is a partner ready to support university hospital clinical research quickly and with high quality. The cell freezing technology at -196°C ensures that cultured cells are ready for effective use in joint research projects. This provides a clearer and more tangible path for physical restoration in neurological, musculoskeletal, and immune system conditions.